

## **Anders Essen-Möller subscribes to his entire stakes in NextCell Pharmas right issue**

**The two largest owners of NextCell Pharma AB ("NextCell" or "The Company") Anders Essen-Möller and Diamyd Medical AB, fully subscribe for their respective shares in NextCells ongoing rights issue. This means that both parties consolidate their ownership interests and that Essen-Möllers ownership in NextCell after the investments increases from approximately SEK 3.6 million to 6.0 million.**

Regarding the ongoing rights issue in NextCell, the principal owner Anders Essen-Möller, also the chairman of the company, has chosen to fully utilize its allotted subscription rights, which means that he has subscribed for shares for approximately SEK 2.4 million, corresponding to 737,279 shares. Furthermore, the principal owner Diamyd Medical has also subscribed for its entire share of approximately SEK 3.2 million, corresponding to 981,394 shares in the Company.

Diamyd Medical and Anders Essen-Möller thereby increase their holdings from 1,472,091 shares and 1,105,918 shares to 2,453,485 shares and 1,843,197 shares, respectively. Diamyd Medical's holding in NextCell Pharma increases from approximately SEK 5.4 million to approximately SEK 8.6 million.

"As a long-term and committed owner in NextCell, Diamyd and Anders Essen-Möller have been of crucial importance to us where we are today. The fact that they are investing further in NextCell is gratifying and emphasizes both their commitment and faith in the company," says Mathias Svahn, CEO of NextCell.

NextCell's CEO, Mathias Svahn, also uses his subscription rights and subscribes 122,398 shares via his company and 27,166 shares privately, a total of 149,564 shares to a value of SEK 0.5 million.

### **Advisors**

Stockholm Corporate Finance is financial advisor and KANTER Advokatbyrå KB legal adviser in connection with the Rights Issue. Hagberg & Aneborn Fondkommission AB is the issuing institution.

*This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 11th of June 2019.*

### **Stay up to date with the latest development in NextCell Pharma**

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

### **For more information, please contact:**

**NextCell Pharma AB (publ)**

Mathias Svahn, CEO  
Tel: +46 (0)8 735 55 95  
E-post: [mathias.svahn@nextcellpharma.com](mailto:mathias.svahn@nextcellpharma.com)

Otto Rydbeck, CEO, Stockholm Corporate Finance  
Tel: +46 (0)8 440 56 40  
E-post: [otto.rydbeck@stockholmcorp.se](mailto:otto.rydbeck@stockholmcorp.se)

**About NextCell Pharma AB:**

---

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.